Klinične študije za Melanom v Ohio
40 študij za Melanom išče udeležence na lokacijah v Ohio.
Mesta v Ohio
- Columbus21 študij
- Cincinnati17 študij
- Cleveland13 študij
- Toledo8 študij
- Akron8 študij
- Dayton7 študij
- Newark3 študij
- Youngstown3 študij
- Findlay3 študij
- Parma3 študij
Uradno besedilo študije (angleško)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- in še 44
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
Vključevanje udeležencevOpazovalna študija
Starost 18–130 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07124000BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Miami Valley Hospital South, Centerville
- Premier Blood and Cancer Center, Dayton
- Miami Valley Hospital North, Dayton
- in še 2
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Oncology Hematology Care Clinical Trials, Cincinnati
- Seidman Cancer Center, Cleveland
- The Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06246916Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Oncology Hematology Care, Cincinnati
- Ohio State University, Columbus
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT05727904A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
Vključevanje udeležencevFaza 2
Do 25 let · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07621614Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Good Samaritan Hospital - Cincinnati, Cincinnati
- in še 5
Vključevanje udeležencevFaza 3
Starost 75 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07068074Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Ohio State University, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06529822A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- in še 56
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Cincinnati Medical Center, Cincinnati
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07287917A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT04913285A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Cleveland Clinic Taussig Cancer Center, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07070232Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- in še 5
Vključevanje udeležencevOpazovalna študija
Do 25 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- University of Cincinnati Cancer Center, Cincinnati
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT05592626Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 1
Starost 18–99 · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT04697576Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Cincinnati, Cincinnati
Vključevanje udeležencevFaza 1/2
Starost 18–70 · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT05361174Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT05588453Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- University of Cincinnati Cancer Center, Cincinnati
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 8. jun. 2026 · NCT03947385Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Christ Hospital Cancer Center, Cincinnati
- Taylor Cancer Research Center, Maumee
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 15. maj 2026 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 13. maj 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Cole Eye Institute-9500 Euclid Ave, Cleveland
- Ohio State Eye and Ear Institute, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The Ohio State University, Columbus
Vključevanje udeležencevFaza 2/3
Vse starosti · Vsi spoli · Posodobljeno 2. apr. 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- Dayton Physician LLC - Englewood, Dayton
- in še 9
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06418204EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 2
Starost 18–99 · Vsi spoli · Posodobljeno 10. mar. 2026 · NCT06223659Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Vse starosti · Vsi spoli · Posodobljeno 9. mar. 2026 · NCT04792463Promoting Immunotherapy Efficacy With Low-Dose Liver RT
- University of Cincinnati Medical Center, Cincinnati
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 27. feb. 2026 · NCT07225036Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- The Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. feb. 2026 · NCT05549297A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Vse starosti · Vsi spoli · Posodobljeno 17. feb. 2026 · NCT04567706Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. dec. 2025 · NCT03567889A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 21. nov. 2025 · NCT05914116Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. okt. 2025 · NCT06249048SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 18. maj 2025 · NCT05970497Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- University Hospitals Avon Health Center, Avon
- Miami Valley Hospital South, Centerville
- University Hospitals Geauga Medical Center, Chardon
- in še 6
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 27. nov. 2024 · NCT03860883A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 25. nov. 2024 · NCT05824975Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.